Repaglinide

Introduction Overview

Generic Name

repaglinide

Brand Name

Prandin

Dosage Form

oral tablet (0.5 mg; 1 mg; 2 mg)

Drug Class

Meglitinides

Pharmacokinetics

Absorption: Repaglinide is rapidly absorbed following oral administration, with peak plasma concentrations typically reached within 1 hour. Its rapid absorption facilitates effective postprandial glucose control by prompting timely insulin release. Several factors, including food intake and gastrointestinal motility, can influence its absorption; bioavailability is high but variable due to first-pass hepatic metabolism. Clinical studies confirm that taking repaglinide within 30 minutes before meals ensures optimal absorption and therapeutic efficacy. Distribution: Following absorption, repaglinide exhibits extensive plasma protein binding, primarily to albumin (>98%), which influences its volume of distribution and pharmacodynamic effects. The volume of distribution is moderate, indicating a distribution predominantly within extracellular fluids and tissues relevant to its site of action, such as pancreatic beta cells. The drug's plasma half-life is short, consistent with its rapid onset and offset of action. Metabolism: Repaglinide undergoes extensive hepatic metabolism, primarily by the cytochrome P450 enzyme CYP3A4, with minor involvement of CYP2C8. Phase I oxidative metabolism transforms repaglinide into inactive metabolites, reducing systemic exposure and terminating its biological activity. The first-pass metabolism significantly reduces the bioavailability, accounting for variability in plasma concentrations. Drug interactions involving CYP3A4 inhibitors or inducers can significantly alter repaglinide plasma levels, necessitating dosage adjustments. Elimination: The elimination of repaglinide is predominantly via hepatic metabolism, with less than 8% excreted unchanged in urine. Metabolites are mainly excreted through bile into feces and also to a lesser extent via urine. The plasma elimination half-life ranges between 1 hour and 1.5 hours, supporting its short duration of action. Impaired hepatic function prolongs elimination and increases plasma concentrations, warranting caution and possible dose modification in liver disease patients. Renal impairment has less impact on elimination due to minimal renal excretion of unchanged drug. Overall, repaglinide's pharmacokinetic profile supports its use in meal-time blood glucose control in type 2 diabetes.

Dosage Forms

Available Dosage Forms: Repaglinide is available exclusively as oral tablets formulated in 0.5 mg, 1 mg, and 2 mg strengths. These immediate-release tablets are designed for rapid absorption, enabling preprandial administration. Dosages for Adults and Adolescents: The adult dosage is individualized based on glycemic response and previous antidiabetic therapy. Typically, dosing begins at 0.5 mg orally before each meal for patients with HbA1c less than 8% or who are antidiabetic naïve. Patients previously treated or with HbA1c above 8% may start at 1 or 2 mg orally preprandially. Doses can be administered 2 to 4 times daily, closely timed before meals, with maximum per meal dose of 4 mg and maximum total daily dose of 16 mg. Dose adjustments are based on fasting and postprandial blood glucose monitoring, with at least one week intervals between titrations to assess response. Specific Patient Populations: Repaglinide is not approved for use in patients under 18 years of age and is contraindicated in type 1 diabetes and diabetic ketoacidosis. Hepatic impairment significantly affects pharmacokinetics and requires cautious use or avoidance. There is limited data on dose modification during renal impairment, although dosing adjustments are commonly unnecessary. Use during pregnancy should weigh the benefits of glycemic control against potential risks; breastfeeding is not recommended. Special attention should be paid to drug interactions and hypoglycemia risk in elderly patients or those on multiple antidiabetic agents.

Mechanism Of Action

Repaglinide belongs to the meglitinide class of oral hypoglycemic agents that function primarily by stimulating insulin secretion from pancreatic beta cells. Its molecular mechanism involves binding selectively to the sulfonylurea receptor 1 (SUR1) subunit of the ATP-sensitive potassium (K_ATP) channels on pancreatic beta-cell membranes. By binding to SUR1, repaglinide closes the K_ATP channel, causing cell membrane depolarization. This depolarization triggers the influx of calcium ions through voltage-dependent calcium channels. The resultant increase in intracellular calcium concentration promotes exocytosis of insulin-containing granules, enhancing insulin secretion into the bloodstream. This insulin release is rapid but short-lived, aligning with the timing of meals to effectively lower postprandial blood glucose. Repaglinide differs from sulfonylureas in that its binding is reversible and it has a shorter half-life, reducing risks of prolonged hypoglycemia. Biochemically, repaglinide acts on a different site than sulfonylureas on the SUR1 receptor, conferring distinct binding characteristics and clinical properties. Clinically, the mechanism translates to improved glycemic control primarily by reducing post-meal glucose excursions without significantly affecting fasting glucose levels. Research comparing repaglinide to other meglitinides and sulfonylureas demonstrates similar efficacy with a more flexible dosing schedule and lower hypoglycemia incidence. Moreover, repaglinide's rapid onset and offset enable tailored insulin secretion responsive to meal timing, offering therapeutic advantages in type 2 diabetes management focused on postprandial hyperglycemia control.

Pharmacological Actions

Stimulates rapid, short-acting insulin secretion from pancreatic beta cells
Lowers postprandial blood glucose levels effectively
Improves overall glycemic control in type 2 diabetes mellitus
Acts via binding to sulfonylurea receptor 1 on ATP-sensitive potassium channels
Induces membrane depolarization and calcium influx in beta cells
Enhances insulin exocytosis without affecting insulin synthesis
Facilitates glucose-dependent insulin release, reducing fasting hypoglycemia risk
Has a rapid onset and short duration of action relative to sulfonylureas
Used as an adjunct to diet and exercise for blood sugar management
Can be combined with other antidiabetic agents for improved control
Exhibits reversible receptor binding allowing flexible dosing
Demonstrates effectiveness in reducing HbA1c levels
Associated with low risk of prolonged hypoglycemia
Metabolized primarily by liver enzymes CYP3A4 and CYP2C8
Influences insulin release without direct effects on insulin sensitivity

Therapeutic Or Clinical Uses

Management of type 2 diabetes mellitus in adults
Adjunct therapy to diet and exercise to improve glycemic control
Treatment targeting reduction of postprandial glucose excursions
Alternative to sulfonylureas in patients intolerant to those agents
Useful in patients requiring rapid and short-acting insulin secretagogue
Can be combined with metformin or thiazolidinediones for combination therapy
Improvement of HbA1c levels in inadequately controlled diabetes
Used in patients with varying baseline HbA1c for glycemic optimization
Management of diabetes when fasting hypoglycemia risk must be minimized
Treatment option in patients not suitable for insulin therapy
Part of individualized diabetic treatment regimens
Control of blood glucose during periods of stress with dose adjustment
Non-approved use may include clinical trials for novel diabetic states
Use in elderly diabetic patients where hypoglycemia risk must be balanced
Adjunct in diabetes management during certain intercurrent illnesses

Side Or Adverse Effects

Hypoglycemia, especially if meals are skipped or dosages are excessive
Nausea and gastrointestinal discomfort including diarrhea
Headache frequently reported during therapy initiation
Back pain and musculoskeletal discomfort
Joint pain (arthralgia) in some patients
Upper respiratory symptoms such as nasal congestion, sneezing, sore throat
Rare but serious hypersensitivity reactions including rash and anaphylaxis
Potential for severe hypoglycemia requiring glucagon injection
Pancreatitis presenting as severe upper abdominal pain radiating to back
Fatigue and weakness possibly related to hypoglycemia episodes
Mild hepatic enzyme elevations have been reported
Edema and fluid retention rarely observed
Weight gain infrequently reported in long-term use
Skin reactions including rash and pruritus
Central nervous system disturbances such as dizziness or anxiety

Precautions

Do not use in type 1 diabetes mellitus or diabetic ketoacidosis
Use cautiously in patients with severe liver impairment due to altered metabolism
Monitor closely for signs of hypoglycemia, especially when combined with other antidiabetics
Avoid administering repaglinide if a meal is skipped to prevent hypoglycemia
Assess renal function, though dosage adjustments are rarely needed in renal impairment
Use caution in elderly patients who may be more susceptible to hypoglycemia
Be wary of drug interactions, particularly with CYP3A4 inhibitors and inducers
Adjust doses downwards when combined with metformin or thiazolidinediones to reduce hypoglycemia risk
Avoid concurrent use with gemfibrozil and NPH insulin due to increased hypoglycemia risk
Not recommended during breastfeeding due to potential excretion in milk
Pregnant patients require careful glycemic control balancing maternal and fetal risks
Educate patients about recognizing and managing symptoms of low blood sugar
Avoid alcohol consumption as it may exacerbate hypoglycemia
Instruct patients on the importance of adherence with meal timing and dosing
Regular monitoring of blood glucose and HbA1c to guide therapy adjustments

Warnings

Contraindicated in patients with type 1 diabetes mellitus
Do not use in diabetic ketoacidosis requiring insulin therapy
Avoid use in severe hepatic impairment due to risk of drug accumulation
Concurrent use with gemfibrozil is contraindicated due to increased hypoglycemia risk
Not recommended for co-administration with NPH insulin (isophane insulin)
May cause serious hypoglycemia, potentially life-threatening without prompt treatment
Monitor liver function tests periodically for early signs of hepatic dysfunction
Risk of pancreatitis necessitates prompt evaluation of unexplained severe abdominal pain
Use with caution in patients with cardiovascular disease due to hypoglycemia risks
Careful dose titration required to avoid overshooting glycemic targets
Consider drug interactions that may modify repaglinide plasma concentrations
Pregnancy and breastfeeding status should be assessed due to limited safety data
Hypoglycemia symptoms may be masked by beta-blockers or other medications
Patients should carry glucagon emergency kit if prescribed
Avoid sudden discontinuation without medical consultation

Contraindication

Type 1 diabetes mellitus
Diabetic ketoacidosis
Severe liver disease
Known hypersensitivity or allergy to repaglinide or any formulation component
Concurrent use with gemfibrozil
Concurrent use with NPH (isophane) insulin
Patients younger than 18 years old
History of severe hypoglycemia resistant to standard treatment
Pregnancy and breastfeeding unless clearly necessary and supervised
Patients with unstable diabetic conditions requiring parenteral insulin
Severe renal impairment with significant metabolic disturbances
Situations where postprandial insulin secretion would be ineffective (e.g., pancreatic beta-cell failure)
Concurrent use with potent CYP3A4 inducers without dose adjustment
Known sulfonylurea allergy (due to similar receptor interactions)
Uncontrolled infection or severe systemic illness impacting glucose metabolism

Drug Interactions

Gemfibrozil markedly increases repaglinide plasma concentrations, raising hypoglycemia risk
CYP3A4 inhibitors (e.g., ketoconazole, erythromycin) increase repaglinide levels
CYP3A4 inducers (e.g., rifampin, carbamazepine) decrease repaglinide effectiveness
Clopidogrel may alter repaglinide metabolism and blood glucose control
Cyclosporine coadministration requires careful monitoring due to pharmacokinetic interaction
NPH insulin combined therapy increases risk of hypoglycemia
Other antidiabetic agents such as metformin and thiazolidinediones may potentiate hypoglycemia
Beta-blockers may mask hypoglycemia symptoms during repaglinide therapy
Warfarin interactions may require monitoring of coagulation parameters
Nonsteroidal anti-inflammatory drugs (NSAIDs) can alter glucose metabolism
Alcohol consumption potentiates hypoglycemic episodes
Herbal products like ginseng or St. John's wort may interfere with glucose control
Drugs altering gastrointestinal motility can affect repaglinide absorption
Corticosteroids and sympathomimetics may antagonize the glucose-lowering effect
Sulfonamides and certain antibiotics may influence repaglinide pharmacodynamics

Preparations Of The Drug

Oral tablet formulation containing repaglinide 0.5 mg
Oral tablet formulation containing repaglinide 1 mg
Oral tablet formulation containing repaglinide 2 mg
Immediate-release tablets designed for preprandial administration
Packaged in blister packs or bottles to maintain stability
Storage recommendations specify room temperature away from heat and moisture
Available as brand name Prandin with FDA-approved manufacturing standards
Formulated with excipients to enhance bioavailability and patient compliance
Standard labeling includes instructions for dosing before meals
No extended-release or injectable formulations currently marketed
Counterfeit risk mitigated by unique packaging identifiers
Patient information leaflets provided with detailed dosage and safety guidance
Supplemental educational materials for healthcare providers and patients
Manufactured under Good Manufacturing Practice (GMP) conditions
Regular batch testing ensures potency and purity